Ingenza has joined forces with leading universities and industrial partners to participate in the ConBioChem collaboration, a translational project focused on the development of novel platform technologies for the continuous bio-production of commodity chemicals. The consortium, led by Professor Gill…
Ingenza has reached a major technical milestone with Syngenta in their collaboration to develop efficient manufacturing technologies for innovative crop protection products. Ingenza’s leadership in industrial biotechnology and synthetic biology has been validated by this application of key microbial gene…
Leading industrial biotechnology company Ingenza has acquired a high performance benchtop bioreactor system to enable faster development of new fermentation processes. The Sartorius ambr® 250 modular system combines automated operation and monitoring with small-scale, single-use fermentation vessels, offering potential benefits…
The UK’s premier industrial biotechnology company Ingenza is working with the National Physical Laboratory and the University of Plymouth to develop a design and manufacturing platform for the production of a new family of antibiotics. The consortium has secured £933k…
Edinburgh-based Ingenza is celebrating after being named the Innovator of the Year at the 2017 Made in Scotland awards, held at the Glasgow Science Centre on the 19th of April. Now in its second year, the awards highlight the achievements…
Ingenza is pleased to announce that it will be hosting representatives of the Japanese government, academic and technology sectors later this month. The Japanese Ministry of Economy, Trade and Industry (METI) delegation will visit the company’s Roslin BioCentre site as…
Ingenza is celebrating reaching the final of both the Life Sciences Company of the Year and the Innovator of the Year categories at the 2017 Made in Scotland awards. Now in its second year, the awards highlight the achievements of…
Ingenza is pleased to announce it has successfully applied for EU H2020 SME Instrument funding of €50,000 for Phase 1 of its innovative SYNBIOMAN project, allowing the company to forge ahead with the development of this novel synthetic biology-driven biomanufacturing…
Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use. This work is part of a collaboration with researchers at the University of Aberdeen and the University…